Optellum, a lung-health AI company in Oxford has entered a strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson. Through the collaboration, Optellum will apply its AI-powered clinical decision support platform with the goal of increasing lung cancer survival rates through early intervention and prevention.
Optellum was co-founded by Oxford cancer researcher Prof. Sir Michael Brady (Department of Oncology) with the mission of seeing every lung disease patient diagnosed and treated at the earliest possible stage, and cured.